The proposed acquisition of Grand Venture Technology will strengthen Aalberts position in APAC. Despite current challenges in key end markets (Automotive, Construction and Machine Building), Aalberts continues to execute on operational improvements, which lay the groundwork for a robust earnings leverage upon revenue recovery. We maintain our Accumulate rating on valuation grounds.
Aalberts: Acquisition of Asian semiconductor player. ASML: Preview 2Q25; building backlog for 2026. BAM: 1H25 preview - YoY improvement from UK. Barco: Preview 1H25F; significant headwinds. Econocom: Acquires four specialist AV companies under ‘One Econocom' strategic plan. Flow Traders: Preview 2Q25. Staffing: Page Group 2Q25 trading update; soft 2Q25 especially in perm; outlook in line. WDP: €41m sale-and-lease back in France
Aalberts N.V.: Aalberts intends to acquire GVT in Southeast Asian semicon market Utrecht, 10 July 2025 Aalberts N.V. has entered into an agreement with Grand Venture Technology Limited (GVT) for the proposed acquisition of 100% of the company. GVT, with its head office in Singapore, operates 6 facilities across Singapore, Malaysia and China, generating an annual revenue of SGD 160 million in 2024 and an EBITDA margin of 19% with approximately 1,800 employees. GVT is a leading precision engineering solutions and service provider of components, mechatronics, assembly and testing mainly f...
Yesterday Immobel issued a trading update that gives comfort in the FY26 bond repayment of EUR 125.0m which was the biggest short term risk of the investment case. This triggered us to increase our TP from EUR 23.0 to EUR 28.0 with a BUY recommendation (prev. accumulate). The reasoning is explained in this new company note. We still don't think the dividend will come back in the next 2 years as the focus remains deleveraging. However, the share price reflected a dilutive capital raise which has ...
Ekopak appoints Jean-Baptiste De Cuyper as new CEO Ekopak (EKOP:xbru), a company specialized in circular water solutions, announces the appointment of Jean-Baptiste De Cuyper as its new CEO. This appointment follows the earlier communication of May 12, 2025, in which the company announced its intention to appoint an external candidate for this key role. The appointment is part of Ekopak's broader efforts to strengthen its governance and management structure. Jean-Baptiste De Cuyper brings more than twenty years of international experience in the water, energy, and infrastructure sectors, t...
Ekopak benoemt Jean-Baptiste De Cuyper als nieuwe CEO Ekopak (EKOP:xbru), een onderneming gespecialiseerd in circulaire wateroplossingen, kondigt de benoeming aan van Jean-Baptiste De Cuyper als nieuwe CEO. Deze aanstelling volgt op de eerdere communicatie van 12 mei 2025 waarin het bedrijf haar intentie bekendmaakte om een externe kandidaat aan te stellen voor deze sleutelrol. De benoeming past binnen Ekopak’s bredere inspanningen om haar governance en managementstructuur te versterken. Jean-Baptiste De Cuyper brengt meer dan twintig jaar internationale ervaring met zich mee in de sectore...
Aalberts reports the progress of its share buyback programme 30 June – 04 July 2025 Aalberts today reports that it has repurchased 2,500 of its own shares in the period from 30 June 2025, up to and including 04 July 2025, for an amount of EUR 77,176.58, so at an average share price of EUR 30.87. This is part of the share buyback programme as announced on 27 February 2025, for a total amount of EUR 75 million. The repurchase of shares commenced on 28 February 2025 and will be completed no later than 24 October 2025. It is intended that the shares will be cancelled following repurchase. Up...
MaaT signed a licensing, distribution, and commercial supply agreement with Clinigen in Europe for Xervyteg (MaaT013, microbiome therapy, enema formulation) in aGvHD for a € 10.5m upfront, € 18m in milestones, and mid-thirties flat royalty on sales. We believe this deal serves as validation of MaaT013's potential, and see the partnership as a de-risking event for MaaT013's commercialisation in Europe, given Clinigen's experience commercialising in haemato-oncology, with 3 products currently on t...
Since the last publication of our Dynamic Top Pick List on 5 June 2025, our selection has seen again a nice outperformance versus the reverence indices (AEX, Bel20 and Eurostoxx50) of on average 3.3%. Our July update brings 3 adjustments to the list : Since being added to the list in December 2024, Fagron's share price has surged +/-22%, driven by strong Q1 2025 results and robust growth across all regions. Fagron reaffirmed its FY25 guidance and unveiled its “Compounding for Growth” strategy, ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.